Edwards Lifesciences Launches Magna Mitral Ease Valve

Preliminary Data on Odyssey Aortic Valve Platform Show Intraoperative Benefits With Rapid Deployment Valve

GENEVA, Switzerland, September 13, 2010 - Edwards Lifesciences Corporation (NYSE:EW), the global leader in the
science of heart valves and hemodynamic monitoring, today announced the U.S.
and European launches of its Carpentier-Edwards PERIMOUNT Magna Mitral Ease
valve, designed to enhance implantation in the challenging mitral position.
The launch is taking place at the 24th Annual Meeting of the European
Association for Cardio-Thoracic Surgery (EACTS).

The Magna Mitral Ease valve incorporates new features to facilitate
access, placement and suturing during both conventional and minimally
invasive heart valve surgeries, especially those using a thoracotomy. Its
product enhancements, such as the tri-colored holder, unique suture guide
line, wide saddle-shaped cuff and new accessories are all designed for easier
implantation. Magna Mitral Ease is based on the clinically proven and durable
Edwards PERIMOUNT mitral valve design, which has more than 250,000 patient
years of experience worldwide. Patients with tissue valves such as Magna
Mitral Ease minimize the need for the lifelong prescription of blood thinners
and its associated risks.

"Magna Mitral Ease can help us to achieve continuous improvements in the
treatment of patients by maintaining the excellent hemodynamics of its
predecessor, while improving and simplifying mitral valve implantation," said
Prof. Jan Gummert, University Hospital of the Ruhr-University of Bochum,
Germany. The clinic at the Ruhr-University was the first worldwide to implant
the Magna Mitral Ease valve using a minimally invasive thoracotomy procedure.

At Saturday's EACTS TechnoCollege, Dr. Malakh Shrestha, Hannover Medical
School, Hannover, Germany, provided a preliminary, single-center case
presentation on Edwards' investigational, minimally invasive, rapid
deployment Odyssey aortic valve platform. This initial series of aortic valve
replacement (AVR) procedures at Hannover using the Odyssey platform
demonstrated an approximately 50 percent reduction in bypass and cross-clamp
times when compared to conventional, isolated aortic valve surgery. The
Odyssey platform is currently being studied in Europe as part of the TRITON
trial, and additional data are expected to be announced after enrollment and
patient follow-up is complete.

"The Odyssey platform is designed to simplify and facilitate minimally
invasive aortic valve surgery, thereby enabling shorter cardiopulmonary
bypass times due to its unique implantation method. We believe these
procedural enhancements may also improve patient outcomes," said Donald E.
Bobo, Jr., Edwards' corporate vice president, heart valve therapy.

Prof. Gummert and Dr. Shrestha provide paid consulting services to
Edwards Lifesciences for educational programs.

About the Carpentier-Edwards PERIMOUNT Magna Mitral Ease

The Carpentier-Edwards PERIMOUNT Magna Mitral Ease heart valve is a
pericardial tissue-based bioprosthetic device for patients requiring
replacement of diseased mitral heart valves. It is based on the Edwards
PERIMOUNT mitral valve design. Multiple studies have demonstrated the
PERIMOUNT Magna Mitral valve's long-term endurance.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves
and hemodynamic monitoring. Driven by a passion to help patients, the company
partners with clinicians to develop innovative technologies in the areas of
structural heart disease and critical care monitoring that enable them to
save and enhance lives. Additional company information can be found at
www.edwards.com.

This news release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements can
sometimes be identified by the use of words such as "may," "will," "should,"
"anticipate," "believe," "plan," "project," "estimate," "expect," "intend,"
or other similar expressions and include, but are not limited to, the timing
and progress of clinical studies relating to the company's heart valve
technologies and the market opportunity for these technologies.
Forward-looking statements are based on estimates and assumptions made by
management of the company and are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Our forward-looking statements
speak only as of the date on which they are made and we do not undertake any
obligation to update any forward-looking statement to reflect events or
circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that expressed
or implied by the forward-looking statements. Factors that could cause actual
results or experience to differ materially from that expressed or implied by
the forward-looking statements are detailed in the company's filings with the
Securities and Exchange Commission including its Annual Report on Form 10-K
for the year ended December 31, 2009.

Edwards, Magna Mitral Ease and Odyssey are trademarks of Edwards
Lifesciences Corporation. Edwards Lifesciences, the stylized E logo,
Carpentier-Edwards, Magna, PERIMOUNT and PERIMOUNT Magna are trademarks of
Edwards Lifesciences Corporation and are registered in the United States
Patent and Trademark Office.

Edwards Lifesciences, Route de L'Etraz 70, 1260 Nyon, Switzerland, Phone: +41-22-787-4300, Fax: +41-22-787-4348; Media Contact: EU: Michael George, +41-22-787-4304; U.S.: Sarah Huoh +1 949-250-5070; Investor Contact: David K. Erickson, +1-949-250-6826